| 53.37 2.68 (5.29%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 66.91 | 1-year : | 72.41 |
| Resists | First : | 57.28 | Second : | 62 |
| Pivot price | 55.65  |
|||
| Supports | First : | 49.66 | Second : | 41.32 |
| MAs | MA(5) : | 53.2 |
MA(20) : | 55.87 |
| MA(100) : | 61.35 |
MA(250) : | 78.88 |
|
| MACD | MACD : | -0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 13.4 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 111.29 | Low : | 47.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LNTH ] has closed above bottom band by 25.1%. Bollinger Bands are 12.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.65 - 54.01 | 54.01 - 54.33 |
| Low: | 49.83 - 50.28 | 50.28 - 50.67 |
| Close: | 52.67 - 53.38 | 53.38 - 54.03 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Mon, 10 Nov 2025
LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Mon, 10 Nov 2025
Investors who lost money on Lantheus Holdings, Inc.(LNTH) should contact The Gross Law Firm about pending Class Action - LNTH - PR Newswire
Fri, 07 Nov 2025
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 68 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 117.9 (%) |
| Shares Short | 7,790 (K) |
| Shares Short P.Month | 7,450 (K) |
| EPS | 3.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.15 |
| Profit Margin | 17.8 % |
| Operating Margin | 23.2 % |
| Return on Assets (ttm) | 13.3 % |
| Return on Equity (ttm) | 24.7 % |
| Qtrly Rev. Growth | -4.1 % |
| Gross Profit (p.s.) | 14.25 |
| Sales Per Share | 22.35 |
| EBITDA (p.s.) | 7.26 |
| Qtrly Earnings Growth | 27.2 % |
| Operating Cash Flow | 527 (M) |
| Levered Free Cash Flow | 295 (M) |
| PE Ratio | 14.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.11 |
| Price to Sales | 2.38 |
| Price to Cash Flow | 6.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|